Triglycerides and cardiovascular disease (Q38240749)

31 August 2017

Triglycerides and cardiovascular disease (English)

1 reference

31 August 2017

1 reference

cardiovascular disease

1 reference

inferred from title

author

Børge G. Nordestgaard

series ordinal

1

object named as

Børge G Nordestgaard

0 references

author name string

Anette Varbo

series ordinal

2

1 reference

PubMed ID

25131982

31 August 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

384

1 reference

31 August 2017

626-635

1 reference

31 August 2017

9943

1 reference

Atherogenesis: a postprandial phenomenon

31 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Remnant cholesterol as a causal risk factor for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Triglycerides and heart disease: still a hypothesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Diagnosis and Management of Type I and Type V Hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Demystifying the management of hypertriglyceridaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Postprandial hypertriglyceridemia as a coronary risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Triglycerides and the Risk of Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Nonfasting triglycerides and risk of ischemic stroke in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Nonfasting hyperlipidemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Fasting time and lipid levels in a community-based population: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Direct visualization of lipid deposition and reverse lipid transport in a perfused artery : roles of VLDL and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Mendelian randomization: prospects, potentials, and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Biological, clinical and population relevance of 95 loci for blood lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Common variants associated with plasma triglycerides and risk for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961177-6

7 January 2021

10.1016/S0140-6736(14)61177-6

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25131982